Completed PHASE3 INTERVENTIONAL NCT00102375

Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer

Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan

Sponsor: AGO Study Group

Conditions Ovarian Cancer

Interventions Topotecan

Updated 6 times since 2017 Last updated: Aug 3, 2006 Started: Dec 31, 1999 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Ovarian Cancer and is currently completed. AGO Study Group leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AGO Study Group

Data source: AGO Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Berlin, Germany , Dresden, Germany , Düsseldorf, Germany , Frankfurt, Germany , Greifswald, Germany , Göttingen, Germany , Hanover, Germany , Karlsruhe, Germany , Kiel, Germany and 6 more locations